drugset / Trial / NCT00922896
Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer
Phase 2
Completed
22 enrolled
Gyeongsang National University Hospital
Chung-Ang University Hospital · collabDong-A University Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.
Timeline
- Start
- 2009-06
- Primary completion
- 2010-08
- Completion
- 2011-05
Outcome
Met primary endpoint
paper The response rate in stage I reached the target (≥3/22,p0010%) established for movement to stage II PMID 22302349 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Erlotinib | Small molecule | 100 mg | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |